Abstract
Under hypoxia, tumor cells, and tumor-associated macrophages produce VEGF (vascular endothelial growth factor), a signaling molecule that induces angiogenesis. The same macrophages, when treated with GM-CSF (granulocyte/macrophage colony-stimulating factor), produce sVEGFR-1 (soluble VEGF receptor-1), a soluble protein that binds with VEGF and inactivates its function. The production of VEGF by macrophages is regulated by HIF-1α (hypoxia inducible factor-1α), and the production of sVEGFR-1 is mediated by HIF-2α. Recent experiments measured the effect of inhibiting tumor growth by GM-CSF treatment in mice with HIF-1α-deficient or HIF-2α-deficient macrophages. In the present paper, we represent these experiments by a mathematical model based on a system of partial differential equations. We show that the model simulations agree with the above experiments. The model can then be used to suggest strategies for inhibiting tumor growth. For example, the model qualitatively predicts the extent to which GM-CSF treatment in combination with a small molecule inhibitor that stabilizes HIF-2α will reduce tumor volume and angiogenesis.
Similar content being viewed by others
References
Anderson, A., & Chaplain, M. A. J. (1998). Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol., 60, 857–900.
Bosco, M. C., Puppo, M., Pastorino, S., Mi, Z., Melillo, G., Massazza, A., Rapisarda, S., & Varesio, L. (2004). Hypoxia selectively inhibits Monocyte Chemoattractant Protein-1 production by macrophages. J. Immunol., 172, 1681–1690.
Braunstein, S., Karpisheva, K., Pola, J., Goldberg, C., Hochman, T., Yee, H., Cangiarella, J., Arju, R., Formenti, S. C., & Schneider, R. J. (2007). A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol. Cell, 28(3), 501–512.
Breward, C. J. W., Byrne, H. M., & Lewis, C. E. (2001). Modeling the interactions between tumour cells and a blood vessel in a microenvironment within a vascular tumour. Eur. J. Appl. Math., 12, 529–556.
Butterworth A, E., & Cater, D. (1967). Effect of lysolecithin on oxygen uptake of tumour cells polymorphonuclear leucocytes lymphocytes and macrophages in vitro. Br. J. Cancer, 21(2), 373389.
Caldwell, J., Locey, B., Clarke, M. F., Emerson, S. G., & Palsson, B. O. (1991). Influence of medium exchange schedules on metabolic, growth, and GM-CSF secretion rates of genetically engineered NIH-3T3 cells. Biotechnol. Prog., 7, 1–8.
Casciari, J. J., Sotirchos, S. V., & Sutherland, R. M. (1988). Glucose diffusivity in multicellular tumor spheroids. Cancer Res., 48, 3905–3909.
Chaplain, M. (1995). The mathematical modeling of tumor angiogenesis and invasion. Acta Biotheor., 43, 387–402.
Chen, Y., Cairns, R., Papandreou, I., Koong, A., & Denko, N. C. (2009). Oxygen consumption can regulate the growth of tumors, a new perspective on the warburg effect. PLoS ONE, 4(9), 27033.
Curry, J., Eubank, T., Roberts, R., Wang, Y., Pore, N., Maity, A., & Marsh, C. (2008). M-CSF signals through the MARK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS ONE, 3(10), e3405.
Eubank, T., Galloway, M., Montague, C., Waldman, W., & Marsh, C. (2003). M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J. Immunol., 175(5), 2637–2643.
Eubank, T., Roberts, R. D., Galoway M., Wang, Y., Cohn, D., & Marsh, C. (2004). GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity, 21, 831–842.
Eubank, T., Roberts, R. D., Khan, M., Curry, J., Nuovo, G. J., Kuppusamyl, P., & Marsh, C. (2009). Granulocyte macrophage Colony-Stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res., 69(5), 2133–2140.
Eubank, T., Roda, J. M., Liu, H., O’Neil, T., & Marsh, C. (2011). Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes. Blood, 117(1), 323–331.
Gabhann, F. M., & Popel, A. S. (2004). Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol., Heart Circ. Physiol., 286, H153–H164.
Girgis-Gabardo, A., & Hassell, J. (2008). Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol. Prog., 22, 801–810.
Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol., 1, 23–35.
Grabhann, F. M., & Popel, A. S. (2003). Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol., Heart Circ. Physiol., 286, H153–H164.
Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., & Kasuga, M. (2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest., 116(6), 1494–1505.
Koshikawa, N., Iyozumi, A., Gassmann, M., & Takenaga, K. (2003). Constitutive upregulation of hypoxia-inducible factor 1α mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor over-expression upon hypoxic exposure. Oncogene, 22, 6717–6724.
Kuratsu, J., Yoshizato, K., Yoshimura, T., Leonard, E. J., Takeshima, H., & Ushio, Y. (1993). Quantitative study of monocyte chemoattractant Protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J. Natl. Cancer Inst., 85, 1836–1839.
Lawichi, S., Szmitkowski, M., & Wojtukiewicz, M. (2006). The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin. Chim. Acta, 371, 112–116.
Leitzel, K., Ettenberg, S., Walsh, R., Abraham, J., Modur, V., Braendle, E., Evans, D., Ali, S., Demers, L., & Lipton, A. (2007). Elevated serum M-CSF level predicts reduced survival in metastatic breast cancer patients. J. Clin. Oncol., ASCO annual meeting proceedings I (25).
Leonard, E., Skeel, A., Yoshimura, T., & Rankin, J. (1991). Secretion of monocyte chemoattractant protein (MCP-1) by human mononuclear phagocytes. Adv. Exp. Med. Biol., 351, 55–64.
Less, J., Skalak, T., Sevick, E., & Jain, R. (1991). Microvascular architecture in a mammary-carcinoma—branching patterns and vessel dimensions. Cancer Res., 51, 265–273.
Li, C. (1982). The glucose distribution in 9L rat brain multicell tumour spheroid and its effect on cell necrosis. Cancer, 50, 2066–2073.
Macdougall, J. D. B., & Mccabe, M. (1967). Diffusion coefficient of oxygen through tissues. Nature, 215, 1173–1174.
Marino, S., Hogue, I., Ray, C., & Kirschner, D. (2008). A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol., 254, 178–196.
Melillo, G., Sausville, E., Cloud, K., Lahusen, T., Varesio, L., & Senderowicz, A. (1999). Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res., 59(21), 5433–5437.
Nalwaya, N., & Deen, W. (2008). Nitric oxide, oxygen, and superoxide formation and consumption in macrophage cultures. Chem. Res. Toxicol., 18, 486–493.
Oren, H., Duman, N., Abacioglu, H., Ozkan, H., & Irken, G. (2001). Association between serum macrophage Colony-Stimulating factor levels and monocyte and thrombocyte counts in healthy, hypoxic, and septic term neonates. Pediatrics, 108(2), 329–332.
Owen, M. R., & Sherratt, J. A. (1997). Pattern formation and spatiotemporal irregularity in a model for macrophage tumour interactions. J. Theor. Biol., 189(1), 63–80.
Owen, M. R., Byrne, H. M., & Lewis, C. E. (2004). Mathematical modeling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J. Theor. Biol., 226, 377–391.
Papayianni, A., Alexopoulos, E., Giamalis, P., Gionanlis, L., Belechri, A., Koukoudis, P., & Memmos, D. (2002). Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol. Dial. Transplant., 17, 435–441.
Paweletz, N., & Knierim, M. (1989). Tumor-related angiogenesis. Crit. Rev. Oncol./Hematol., 9, 197–242.
Pettet, G., Byrne, H., McElwain, D., & Norbury, J. (1996). A model of wound-healing angiogenesis in soft tissue. Math. Biosci., 136, 35–63.
Pettet, G., Please, C., & Tindall, M. (2001). The migration of cells in multicell tumor spheroids. Bull. Math. Biol., 63, 231–257.
Plank, M., Sleeman, B., & Jones, P. F. (2004). A mathematical model of tumour anglogenesis, regulated by vascular endothelial growth factor and the angiopoietins. J. Theor. Biol., 229, 435–454.
Pollard, J. W. (1997). Role of colony-stimulating factor-1 in reproduction and development. Mol. Reprod. Dev., 46, 54–60.
Pyaskovskaya, O. N., Kolesnik, D. L., Kolobov, A. V., Vovyanko, S. I., & Solyanik, G. I. (2008). Analysis of growth kinetics and proliferative heterogeneity of lewis lung carcinoma cells growing as unfed culture. Exp. Oncol., 30(4), 269–275.
Qian, B., Deng, Y., Hong Im, J., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009). A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE, 4(8), e6562.
Rapella, A., Negrioli, A., Melillo, G., Pastorino, S., Varesio, L., & Bosco, M. (2002). Flavopirisol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int. J. Cancer, 99, 658–664.
Roda, J. M., Summer, L. A., Evans, R., Philips, G. S., Marsh, C. B., & Eubank, T. D. (2011). Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J. Immunol., 187, 1970–1976.
Roda, J., Wang, Y., Sumner, L., Phillips, G., Eubank, T., & Marsh, C. (2012) Stabilization of HIF-2α induces SVEGFR-1 production from Tumor-associated macrophages and enhances the Anti-tumor effects of GM-CSF in murine melanoma model. J. Immunol., 189, 3168–3177.
Schugart, R. C., Friedman, A., Zhao, R., & Sen, C. K. (2008). Wound angiogenesis as a function of tissue oxygen tension. Proc. Natl. Acad. Sci. USA, 105(7), 2628–2633.
Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev., 3, 721–732.
Shang, Z., Li, Z., & Li, J. (2006). VEGF is up-regulated by hypoxic stimulation and related to tumor angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int. J. Oral Maxillofac. Surg., 35, 533–538.
Stokes, C., & Lauffenburger, D. (1991). Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. J. Theor. Biol., 152, 377–403.
Szomolay, B., Eubank, T., Roberts, R., Marsh, C., & Friedman, A. (2012). Modeling the inhibition of breast cancer growth by GM-CSF. J. Theor. Biol., 303, 141–151.
Tang, S., Liu, H., Rao, Q., Geng, Y., Zheng, G., Zheng, D., & Wu, K. (2000). Internalization and half-life of membrane-bound macrophage colony-simulating factor. Chin. Sci. Bull., 45(18), 1697–1703.
Utting, J. C., Flanagan, A. M., Brandao-Burch, A., Orriss, I. R., & Arnett, T. R. (2010). Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochem. Funct., 28(5), 374–380.
Varney, M., Olsen, K. J., Mosley, R., & Singh, R. (2005). Paracrine regulation of vascular endothelial growth factor-an expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-simulating factor. J. Interferon Cytokine Res., 25(11), 674–683.
Vaupel, P., Mayer, A., Briest, S., & Hockel, M. (2003). Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res., 63, 7634–7637.
Vicioso, L., Gonzalez, F., Alvarez, M., Ribelles, N., Molina, M., Marquez, A., Perez, L., Matilla, A., & Alba, E. (2006). Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am. J. Clin. Pathol., 125, 111–118.
Vincensini, D., Dedieu, V., Eliat, P. A., Vincent, C., Bailly, C., de Certaines, J., & Joffre, F. (2007). Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. J. Magn. Reson. Imaging, 25, 293–302.
Ward, J., & King, J. (1997). Mathematical modeling of avascular tumor growth. IMA J. Math. Appl. Med. Biol., 14, 39–69.
Ward, J., & King, J. (1999). Mathematical modeling of avascular tumor growth II: modeling growth saturation. IMA J. Math. Appl. Med. Biol., 16, 171–211.
Wathen, K., Sarvela, J., Stenman, F., Stenman, U., & Vuorela, P. (2011). Changes in serum concentrations of soluble vascular endothelial growth factor receptor-1 after pregnancy. Hum. Reprod., 26(1), 221–226.
Williams, M., Kelsey, S., & Newland, A. (1999). GM-CSF and stimulation of monocyte/macrophage function in vivo relevance and in vitro observations. Eur. J. Cancer, 35(3), S1–S22.
Wu, F. T. H., Stefanini, M. O., Gabhann, F. M., & Popel, A. S. (2009). A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE, 4(4), e5108.
Wu, F. T. H., Stefanini, M. O., Gabhann, F. M., Kontos, C. D., Annex, B. H., & Popel, A. S. (2010). VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am. J. Physiol., Heart Circ. Physiol., 298, H2174–H2191.
Acknowledgements
This work was supported in part by National Science Foundation Award 0635561, NCI 5R00CA131552 (T.D.E.), and R01 HL067167 (C.B.M.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, D., Roda, J.M., Marsh, C.B. et al. Hypoxia Inducible Factors-Mediated Inhibition of Cancer by GM-CSF: A Mathematical Model. Bull Math Biol 74, 2752–2777 (2012). https://doi.org/10.1007/s11538-012-9776-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-012-9776-3